Kamada (KMDA) Cash & Equivalents (2012 - 2026)
Kamada (KMDA) posted quarterly Cash & Equivalents of $32.9 million for Q1 2026, down 56.82% year-on-year from $76.2 million in Q1 2025, and down 56.38% on a QoQ basis from $75.5 million in Q4 2025.
Kamada (KMDA) Cash & Equivalents (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Cash & Equivalents for 15 consecutive years, with $32.9 million the latest figure, recorded in Q1 2026.
- Quarterly Cash & Equivalents fell 56.82% year-over-year to $32.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.9 million (down 56.82% YoY) and the FY2025 annual result came in at $75.5 million, down 3.78% from the prior year.
- Cash & Equivalents retreated to $32.9 million in Q1 2026 per KMDA's latest filing, from $75.5 million in the prior quarter.
- Over the last five years, Cash & Equivalents for KMDA reached as high as $31.3 billion in Q3 2022 and fell as low as $29933.0 in Q2 2022.
- A 5-year average of $1.9 billion and a median of $55.6 million in 2023 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 99.96% — and 2023, when it jumped 72689.23%.
- Year by year, Cash & Equivalents stood at $34.3 million in 2022, then jumped by 62.42% to $55.6 million in 2023, then jumped by 40.97% to $78.4 million in 2024, then fell by 3.78% to $75.5 million in 2025, then sank by 56.38% to $32.9 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $32.9 million, $75.5 million, and $72.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 1.76 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 3.79 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.28 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 33.59 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 266.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Kamada | 401.22 Mn | 328.07 Mn | 19.12 Mn | 32.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.92 Mn |
| Dec 31, 2025 | 75.47 Mn |
| Sep 30, 2025 | 72.00 Mn |
| Jun 30, 2025 | 65.99 Mn |
| Mar 31, 2025 | 76.25 Mn |
| Dec 31, 2024 | 78.44 Mn |
| Sep 30, 2024 | 72.00 Mn |
| Jun 30, 2024 | 56.55 Mn |
| Mar 31, 2024 | 48.19 Mn |
| Dec 31, 2023 | 55.64 Mn |
| Sep 30, 2023 | 52.60 Mn |
| Jun 30, 2023 | 21.79 Mn |
| Mar 31, 2023 | 27.12 Mn |
| Dec 31, 2022 | 34.26 Mn |
| Sep 30, 2022 | 31.25 Bn |
| Jun 30, 2022 | 29,933.00 |
| Mar 31, 2022 | 21.97 Mn |
| Dec 31, 2021 | 18.59 Mn |
| Sep 30, 2021 | 99.84 Mn |
| Jun 30, 2021 | 68.42 Mn |